Trethera News

Gloved hand of a scientist in a lab writing on a digital stilus with a digital pen.

Scientific microscope with visual representation of DNA helix

Trethera Announces Invited Speaker Presentations at the Purine and Pyrimidine Society Symposium and General Assembly

June 28, 2023

Los Angeles, June 28, 2023 — Trethera Corporation, a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announces two upcoming presentations at the 20th Annual Symposium and General Assembl

Read More 

Trethera Receives Grant from National Institute of Allergy and Infectious Diseases for the Advancement of TRE-515 in Lupus



June 27, 2023

Los Angeles, June 27, 2023 — Trethera Corporation, a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced today that it was awarded a $0.6M Small Business Technology Transfer (STTR)

Read More 

Trethera Receives $2 Million National Cancer Institute Grant for Advancement of Clinically Relevant Biomarkers in Phase 1 Trial



May 30, 2023

Los Angeles, May 30, 2023 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced today that it was awarded a $2 million Small Business Innovativ

Read More 

Dose Escalation Portion of Phase 1 Solid Tumors Trial Produces Favorable Results in Heavily Pretreated Solid Tumor Patients



March 15, 2023

Los Angeles, March 15, 2023 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, received a unanimous recommendation from the independent safety review

Read More 

Trethera Announces Appointment of Laurent Dubois to Board of Directors



February 15, 2023

Los Angeles, February 15, 2023 — Trethera Corporation (“Trethera”), a clinical-stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced today the appointment of Laurent Dubois to the Trethera Bo

Read More 